| |
|
|
|
| deaths (OS) | progression or deaths (PFS) | RFS/DFS |
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population |
|
| Ipilimumab (10 mg/kg) vs. interferon alpha | 1 | 0.88 [0.69; 1.12], 1 RCT, I2=0%
inconclusive result | - | 0.84 [0.65; 1.09], 1 RCT, I2=0%
inconclusive result |
| ipilimumab alone vs. interferon alpha | 1 | 0.83 [0.70; 0.98], 2 RCTs, I2=0% conclusive
low degree of certainty | - | 0.85 [0.71; 1.01], 2 RCTs, I2=0%
inconclusive result |
|
| Ipilimumab (10 mg/kg) vs. placebo | 1 | 0.72 [0.58; 0.89], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - | 0.75 [0.63; 0.89], 1 RCT, I2=0% conclusive
unassessable degree of certainty |
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive |
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population |
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant |
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild |
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population |
|
| ipilimumab alone vs. gp100 | 1 | 0.66 [0.51; 0.86], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - | - |
| ipilimumab plus gp100 vs. gp100 | 1 | 0.68 [0.55; 0.85], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - | - |
|
| Ipilimumab (10 mg/kg) vs. ipilimumab alone | 1 | 0.84 [0.71; 1.00], 1 RCT, I2=0% conclusive
unassessable degree of certainty | 0.89 [0.66; 1.21], 1 RCT, I2=0%
inconclusive result | - |
| ipilimumab plus gp100 vs. ipilimumab alone | 1 | 1.04 [0.83; 1.30], 1 RCT, I2=0%
inconclusive result | - | - |
|
| ipilimumab plus SoC vs. placebo plus SoC | 1 | 0.72 [0.59; 0.87], 1 RCT, I2=0% conclusive
unassessable degree of certainty | 0.76 [0.63; 0.92], 1 RCT, I2=0% conclusive
unassessable degree of certainty | - |
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant |
